Shares of PharmaCyte Biotech, Inc. (NASDAQ:PMCB – Get Free Report) traded up 12.4% on Thursday . The company traded as high as $1.83 and last traded at $1.81. 129,298 shares were traded during mid-day trading, an increase of 499% from the average session volume of 21,600 shares. The stock had previously closed at $1.61.
PharmaCyte Biotech Trading Down 2.8 %
The business has a fifty day simple moving average of $1.61 and a two-hundred day simple moving average of $1.71. The company has a market cap of $12.27 million, a PE ratio of 3.32 and a beta of -0.18.
PharmaCyte Biotech (NASDAQ:PMCB – Get Free Report) last issued its earnings results on Friday, December 13th. The company reported ($0.29) earnings per share (EPS) for the quarter.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
Featured Stories
- Five stocks we like better than PharmaCyte Biotech
- How Can Investors Benefit From After-Hours Trading
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- What is diluted earnings per share (Diluted EPS)?
- DuPont’s Electronics Spinoff: The Start of Something Big
- Retail Stocks Investing, Explained
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
